Literature analysis of tislelizumab-induced Stevens-Johnson syndrome and toxic epidermal necrolysis
- VernacularTitle:替雷利珠单抗致史-约综合征和中毒性表皮坏死松解症的文献分析
- Author:
Rui HAN
1
;
Mingxi SHEN
2
;
Hua YANG
3
;
Zhaoshuai JI
3
Author Information
1. Dept. of Pharmacy，Tsinghua University Hospital，Beijing 100084，China
2. Quality and Technology Department，No.6 Traditional Chinese Medicine Factory，Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited，Tianjin 300401，China
3. Dept. of Pharmacy，Beijing Tsinghua Changgung Hospital，School of Clinical Medicine，Tsinghua Medicine，Tsinghua University，Beijing 102218，China
- Publication Type:Journal Article
- Keywords:
tislelizumab;
Stevens-Johnson syndrome;
toxic epidermal necrolysis;
adverse drug reactions;
literature analysis
- From:
China Pharmacy
2025;36(16):2046-2050
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the clinical characteristics of Stevens-Johnson syndrome （SJS） and toxic epidermal necrolysis （TEN） induced by tislelizumab， providing evidence for clinical medication safety. METHODS Case reports of tislelizumab-related SJS/TEN were retrieved from CNKI， VIP， Wanfang Data， PubMed， ScienceDirect， and Embase. Descriptive analysis was performed. RESULTS Seventeen cases from 17 publications were included （SJS 4 cases， TEN 13 cases）. Among them， there were 10 males and 7 females. Twelve patients were aged between 70 and 79 years. The predominant tumor type was lung cancer （10 cases）. Thirteen patients received combination therapy with chemotherapeutic drugs. The median onset time of SJS/ TEN was 26 （4， 104） days. Nine patients developed SJS/TEN after the first administration of the drug. Sixteen patients exhibited prodromal rash symptoms， primarily characterized by severe skin damage such as skin detachment， accompanied by mucosal injury. Sixteen patients improved after symptomatic treatment， while one patient died. CONCLUSIONS Tislelizumab-associated SJS/TEN risk is higher in elderly patients， males， those with lung cancer and those receiving combination chemotherapy. Mucosal lesions and atypical rashes may indicate the early onset of SJS/TEN. During clinical use， pharmaceutical care can be carried out through measures such as identifying high-risk populations， closely monitoring skin symptoms from the first administration to the fifth treatment cycle， and enhancing patient education. When relevant symptoms occur， the medication should be promptly discontinued and symptomatic treatment should be administered to ensure the patient’s medication safety.
